Does Immunosuppressive Therapy Improve Outcomes in Graves' Disease? A Systematic Review and Meta-Analysis

Thyroid

Volumn 26, Issue 5, 2016, Pages 634-640

  Struja, Tristan ^a   Guebelin, Larissa ^a   Kutz, Alexander ^a   Fehlberg, Hannah ^a   Mueller, Beat ^a,b   Schuetz, Philipp ^a,b  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DEXAMETHASONE; IMMUNOSUPPRESSIVE AGENT; OCTREOTIDE; RITUXIMAB; THYROTROPIN RECEPTOR ANTIBODY; ANTITHYROID AGENT;

ARTICLE; CHILL; EMBASE; FEVER; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENCE RISK; RELAPSE; RISK; SYSTEMATIC REVIEW; COMBINATION DRUG THERAPY; RECURRENT DISEASE; SECONDARY PREVENTION; TREATMENT OUTCOME;

ANTITHYROID AGENTS; DRUG THERAPY, COMBINATION; GRAVES DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECURRENCE; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84968860910     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2015.0647     Document Type: Article

References (35)

1. Genovese BM, Noureldine SI, Gleeson EM, Tufano RP, Kandil E 2013 What is the best definitive treatment for Graves' disease? A systematic review of the existing literature. Ann Surg Oncol 20:660-667.
2. Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P 2015 Autoimmune thyroid disorders. Autoimmun Rev 14:174-180.
3. Orgiazzi J 2012 Thyroid autoimmunity. Presse Med 41: e611-625.
4. Franklyn JA, Boelaert K 2012 Thyrotoxicosis. Lancet 379: 1155-1166.
5. Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS 2013 Comparative effectiveness of therapies for Graves; hyperthyroidism: A systematic review and network meta-analysis. J Clin Endocrinol Metab 98: 3671-3677.
6. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS 2010 Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev CD003420.
7. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D 2009 The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100.
8. Higgins JPT, Green S (Eds) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). Available at: http://handbook.cochrane.org/(accessed October 16, 2015).
9. El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L 2007 B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: A controlled pilot study. J Clin Endocrinol Metab 92:1769-1772.
10. El Fassi D, Hegedüs L, Skjoedt MO, Banga JP, Nielsen CH 2009 Detrimental and protective roles of B cells. Lessons learned from administration of rituximab to patients with Graves' disease. Eur J Immunol 39:S660.
11. El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedü s L, Nielsen CH 2009 Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 130:252-258.
12. Heemstra KA, Toes RE, Sepers J, Pereira AM, Corssmit EP, Huizinga TWJ, Romijn JA, Smit JW 2008 Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol 159:609-615.
13. Scottish Intercollegiate Guidelines Network (SIGN). Available at: www.sign.ac.uk/index.html (accessed October 16, 2015).
14. Mantel N, Haenszel W 1959 Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748.
15. DerSimonian R, Laird N 2015 Meta-analysis in clinical trials revisited. Contemp Clin Trials 45:139-145.
16. Leon-Guerrero A, Frankfort-Nachmias C 2012 Essentials of Social Statistics for a Diverse Society. SAGE, Thousand Oaks, CA.
17. Higgins JPT, Thompson SG, Deeks JJ, Altman DG 2003 Measuring inconsistency in meta-analyses. BMJ 327:557-560.
18. Egger M, Davey Smith G, Schneider M, Minder C 1997 Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634.
19. Obiols Alfonso G, Mesa Manteca J, Simo Canonge R, Garcia Pascual L, Garcia Alonso C, Tresanchez Trias JM 1988 Effect of carbimazole and dexamethasone on the TSH bond (TBII) inhibiting immunoglobulins in Graves-Basedow disease. Rev Clin Esp 183:401-404.
20. Yu W, Zhang L, Zhang W, Liu Z, Chen X 2012 Therapeutic effect and safety of local intrathyroid injection of immunosuppressive agents in the treatment of recurrent toxic diffuse goiter associated with hyperthyroidism. Pharm Care Res 12:295-298.
21. Chen L, Wang Hq, Gao Yy, Liang J, Wang M, Bai J, Qi Wb, Zhang Js, Zhang J, Ren Jq, Li Hq 2008 Comparison of methimazole/hydrocortisone ointment with oral methimazole in patients with graves disease: A prospective, randomized, open-label, parallel-group, 18-month study. Curr Ther Res Clin Exp 69:305-317.
22. Huszno B, Trofimiuk M, Golkowski F, Plinta T, Szybiński Z 2004 Assessment of early immunosuppressive therapy in the prevention of complications of Graves' disease. Przeglaxd lekarski 61:868-871.
23. Mao XM, Li Hq, Li Q, Li DM, Xie XJ, Yin GP, Zhang P, Xu XH, Wu JD, Chen SW, Wang SK 2009 Prevention of relapse of Graves' disease by treatment with an intrathyroid injection of dexamethasone. J Clin Endocrinol Metab 94: 4984-4991.
24. Kubota S, Ohye H, Nishihara E, Kudo T, Ito M, Fukata S, Amino N, Kuma K, Miyauchi A 2005 Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH receptor antibodies and clinical outcome in Graves' disease. Endocr J 52:735-741.
25. Jonas M, Ambroziak U, Bednarczuk T, Nauman J 2006 Predicting a relapse of Graves' hyperthyroidism in adults during the early phase of treatment with anti-thyroid drugs. Endokrynol Pol 57:596-604.
26. Lee YH, Baek JH, Jung SL, Kwak JY, Kim J, Shin JH 2015 Ultrasound-guided fine needle aspiration of thyroid nodules: A consensus statement by the Korean Society of Thyroid Radiology. Korean J Radiol 16:391-401.
27. Minakaran N, Ezra DG 2013 Rituximab for thyroidassociated ophthalmopathy. Cochrane Database Syst Rev 5:CD009226.
28. Salvi M, Campi I 2015 Medical treatment of Graves' orbitopathy. Horm Metab Res 47:779-788.
29. Nygaard B 2010 Hyperthyroidism (primary). BMJ Clin Evid 2010 Jul 19;2010. pii: 0611.
30. Fardet L, Feve B 2014 Systemic glucocorticoid therapy: A review of its metabolic and cardiovascular adverse events. Drugs 74:1731-1745.
31. Conn HO, Poynard T 1994 Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 236:619-632.
32. Hooft, Cornelis S. van der, Heeringa J, Brusselle GG, Hofman A, Witteman JCM, Kingma JH, Sturkenboom, Miriam CJM, Stricker BHC 2006 Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 166:1016-1020.
33. Souverein PC, Berard A, van Staa TP, Cooper C, Egberts ACG, Leufkens HGM, Walker BR 2004 Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 90:859-865.
34. Wei L, MacDonald TM, Walker BR 2004 Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141:764-770.
35. Evans R, Salama AD 2014 Update on rituximab: an established treatment for all immune-mediated kidney diseases? Nephron Clin Pract 126:97-109.